Enoxacin Tablets

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. The antibacterial activity against anaerobic bacteria is poor. Enoxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

Enoxacin.

This product is off-white or slightly yellow tablets or film-coated tablets.

Applicable to infections caused by sensitive bacteria: 1. Urinary and reproductive system infections, including simple and complicated urinary tract infections, bacterial prostatitis, urethritis or cervicitis caused by Neisseria gonorrhoeae (including those caused by enzyme-producing strains). 2. Respiratory tract infections, including acute bronchial infections and lung infections caused by sensitive Gram-negative bacilli. 3. Gastrointestinal infections caused by Shigella, Salmonella, enterotoxigenic Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus, etc. 4. Typhoid fever. 5. Bone and joint infections. 6. Skin and soft tissue infections. 7. Systemic infections such as sepsis.

Oral. Common dosage for adults: 1. Bronchial infection: 0.3-0.4g once, twice a day, 7-14 days of treatment. 2. Acute simple lower urinary tract infection: 0.2g once, twice a day, 5-7 days of treatment; complicated urinary tract infection: 0.4g once, twice a day, 10-14 days of treatment. 3. Simple gonorrheal Neisseria urethritis: 0.4g once, single dose. 4. Intestinal infection: 0.2g once, twice a day, 5-7 days of treatment. 5. Typhoid fever: 0.4g once, twice a day, 10-14 days of treatment.

1. Gastrointestinal reactions are relatively common and may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. 2. Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3. Allergic reactions: rash, skin itching, and occasionally exudative erythema multiforme and angioedema. A small number of patients have photosensitivity reactions. 4. Occasionally, the following may occur: (1) Epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, and tremors. (2) Interstitial nephritis manifestations such as hematuria, fever, and rash. (3) Phlebitis. (4) Crystalluria, which is more common when used in high doses. (5) Joint pain. 5. A small number of patients may experience elevated serum aminotransferases, elevated blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

Patients who are allergic to this product and fluoroquinolones or lack glucose-6-phosphate dehydrogenase are contraindicated to use this product.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1 Taking this drug with food may affect the oral absorption of this drug. It is advisable to take this drug on an empty stomach or at least 1 hour before a meal and at least 2 hours after a meal. The reduction of gastric acid may also reduce the absorption of this drug after oral administration. 2 Since Escherichia coli is currently resistant to fluoroquinolones, urine culture specimens should be collected before administration, and the medication should be adjusted based on the bacterial drug sensitivity results. 3 Crystalluria may occur when this product is used in large doses or when the urine pH value is above 7. To avoid the occurrence of crystalluria, it is advisable to drink more water and keep the 24-hour urine output above 1200ml. 4 For patients with impaired renal function, the dosage needs to be adjusted according to renal function. 5 Moderate to severe photosensitivity reactions may occur when using fluoroquinolones. When using this product, excessive exposure to sunlight should be avoided. If photosensitivity reactions occur, the drug should be discontinued. 6. When liver function is impaired, if it is severe (cirrhosis and ascites), drug clearance may be reduced, blood drug concentration may increase, and this is especially obvious in patients with both liver and kidney function impairment. The use of this drug should be done after weighing the pros and cons, and the dosage should be adjusted. 7. Patients with existing central nervous system diseases, such as epilepsy and a history of epilepsy, should avoid using this drug. When indicated, the use of this drug should be done after carefully weighing the pros and cons.

Keep away from light and store in sealed container.

0.1g

24 months

Chongqing Qingyang Pharmaceutical Co., Ltd.

• Founded in:

  2002-05-21

• Address:

  Room 7-1, Building 1, No. 2, Gang'an 2nd Road, Jiangbei District, Chongqing

• Tax NO.:

  915001057365937855

• Registered Funds:

  100.764 million yuan

• Website:

  Log in to view

• Email:

  Log in to view